Generalized pustular psoriasis following withdrawal of efalizumab.

Authors
Category Primary study
JournalJournal of drugs in dermatology : JDD
Year 2004
Efalizumab is one of the new biologic therapies targeting T-lymphocyte activity for the treatment of chronic plaque psoriasis. Common adverse effects include headaches, nonspecific infection, nausea, chills, and fever. Rebound of psoriasis following discontinuation of the drug has been reported. Relapse events can manifest as recurrent plaque psoriasis, guttate psoriasis, psoriatic erythroderma, and pustular psoriasis. We report a second case of withdrawal flare resulting in generalized pustular psoriasis.
Epistemonikos ID: 9a514554d194624201aac268890f5e5091eb6ea0
First added on: Feb 15, 2022